Table 3.
Effect of long-term intracerebroventricular infusion of CRH on plasma TNF, IL-1, and IL-6 bioactivity, 3 and 6 hr after the intraperitoneal administration of LPS
| 3 hr after LPS | 6 hr after LPS | |||
|---|---|---|---|---|
| Intracerebroventricular vehicle | Intracerebroventricular CRH | Intracerebroventricular vehicle | Intracerebroventricular CRH | |
| TNF (pg/ml) | 1045 ± 374 (6) | 1260 ± 203 (6) | 38 ± 8 (5) | 158 ± 52 (4) |
| IL-1 (IU/ml) | 36.04 ± 10.13 (11) | 82.56 ± 18.06 (9)3-150 | n.d. | n.d. |
| IL-6 (IU/ml) | 70,928 ± 22,004 (6) | 197,654 ± 59,271 (6)3-150 | 15,187 ± 5406 (5) | 24,949 ± 8530 (4) |
Vehicle (1 μl/hr) or CRH (1 μg · μl−1 · hr−1) was infused intracerebroventricularly into rats, which were then given injections of LPS (100 μg/kg body weight) on day 7 of the intracerebroventricular treatment. Three or six hours after the injection of LPS, rats were killed and blood was collected for the subsequent measurement of plasma cytokines by bioassay techniques. The number of animals in each experimental group is in parentheses. Data are mean ± SEM (for further details see Materials and Methods). n.d., Not detectable.
F3-150: p < 0.05 compared with i.c.v. vehicle-treated rats [Student’s t test (IL-1); Duncan multiple range test (IL-6)].